Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Protocol | Alliance A041501 |
---|---|
Cancer Type: | NEWLY DIAGNOSED PRECURSOR B-CELL ALL |
Fast Facts |
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ASCT2031 |
---|---|
Cancer Type: | leukemia |
Fast Facts |
COG-ASCT2031: A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
Age: 6 months to <22 years at enrollment
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ACCL1931 |
---|---|
Cancer Type: | ALL |
Fast Facts |
COG-ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Age: ≥15 and <40 years at time of diagnosis.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A041701 |
---|---|
Cancer Type: | ACUTE MYELOID LEUKEMIA |
Fast Facts |
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1925 |
---|---|
Cancer Type: | CLL/SLL |
Fast Facts |
RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NHLBI-MDS |
---|---|
Cancer Type: | Myelodysplastic Syndromes |
Fast Facts |
The National Myelodysplastic Syndromes (MDS) Study
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AALL15P1 |
---|---|
Cancer Type: | Acute Lymphoblastic Leukemia (ALL) |
Fast Facts |
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
Infants Less than 1 Year of Age on the Date of Diagnosis are Eligible; Infants must be >36 Weeks Gestational Age at the Time of Enrollment.
Protocol | COG ACCL20N1CD |
---|---|
Cancer Type: | ALL |
Fast Facts |
COG ACCL20N1CD: Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
Protocol | COG AALL1621 |
---|---|
Cancer Type: | Relapsed Refractory CD22 B-ALL |
Fast Facts |
A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.
AALL1621 has been temporarily closed to accrual as of September 18, 2023, pending an evaluation of patients currently enrolled on this study.
Protocol | COG AALL1631 |
---|---|
Cancer Type: | Ph+ ALL |
Fast Facts |
International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Age: > 1 Year and < 21 Years at ALL Diagnosis
Protocol | COG AALL1731 |
---|---|
Cancer Type: | B-ALL, B-LLy |
Fast Facts |
A Phase III Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Patients must be ≥ 365 Days and < 10 Years of Age (B-ALL Patients without DS)
Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-ALL Patients with DS)
Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-LLy Patients with or without DS
Temporary Closure to Accrual as of 12/19/2022
Protocol | COG AALL1732 |
---|---|
Cancer Type: | B-ALL, B-LLy |
Fast Facts |
A Phase III Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Patients must be > 365 Days and < 25 Years of Age
Protocol | COG AALL1821 |
---|---|
Cancer Type: | B-ALL |
Fast Facts |
COG AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse
Temporary Closure to Accrual as of 12/19/2022
Protocol | COG AAML18P1 |
---|---|
Cancer Type: | Chronic Myeloid Leukemia |
Fast Facts |
COG AAML18P1
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Patient must have been diagnosed with CML-CP at less than 18 years of age
Patient mustbe less than 25 years of age at enrollment
Protocol | COG AAML1831 |
---|---|
Cancer Type: | de nova AML |
Fast Facts |
COG-AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
Patients must be less than 22 years of age at the time of study enrollment.
Protocol | COG APAL2020SC |
---|---|
Cancer Type: | Relapsed Leukemia |
Fast Facts |
COG APAL2020SC
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
Patients must be less than 22 years of age at the time of study enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.